Reply to: Comments on “Randomized, two-arm, non-comparative phase 2 study of olaparib plus cediranib or durvalumab in HRR-mutated, platinum-resistant ovarian cancer: A substudy of KGOG 3045”

Yoo Na Kim; Je Gun Joung; Eunhyang Park; Jae Weon Kim; Jung Bok Lee; Jinyeong Lim; Sunghoon Kim; Chel Hun Choi; Hee Seung Kim; Jongsuk Chung; Byoung Gie Kim; Jung Yun Lee

doi:10.1002/ijc.34786

Reply to: Comments on “Randomized, two-arm, non-comparative phase 2 study of olaparib plus cediranib or durvalumab in HRR-mutated, platinum-resistant ovarian cancer: A substudy of KGOG 3045”

Yoo Na Kim
, Je Gun Joung
, Eunhyang Park
, Jae Weon Kim
, Jung Bok Lee
, Jinyeong Lim
, Sunghoon Kim
, Chel Hun Choi
, Hee Seung Kim
, Jongsuk Chung
, Byoung Gie Kim
, Jung Yun Lee

Department of Obstetrics and Gynecology

Yonsei University
CHA University
Seoul National University
University of Ulsan
Sungkyunkwan University
Geninus Inc.

Research output: Contribution to journal › Letter › peer-review

Original language	English
Pages (from-to)	764-765
Number of pages	2
Journal	International Journal of Cancer
Volume	154
Issue number	4
DOIs	https://doi.org/10.1002/ijc.34786
State	Published - 15 Feb 2024

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Access to Document

10.1002/ijc.34786

Cite this

Kim, Y. N., Joung, J. G., Park, E., Kim, J. W., Lee, J. B., Lim, J., Kim, S., Choi, C. H., Kim, H. S., Chung, J., Kim, B. G., & Lee, J. Y. (2024). Reply to: Comments on “Randomized, two-arm, non-comparative phase 2 study of olaparib plus cediranib or durvalumab in HRR-mutated, platinum-resistant ovarian cancer: A substudy of KGOG 3045”. International Journal of Cancer, 154(4), 764-765. https://doi.org/10.1002/ijc.34786

@article{3e517311f2b74332a7ba94ccd281885e,

title = "Reply to: Comments on “Randomized, two-arm, non-comparative phase 2 study of olaparib plus cediranib or durvalumab in HRR-mutated, platinum-resistant ovarian cancer: A substudy of KGOG 3045”",

author = "Kim, \{Yoo Na\} and Joung, \{Je Gun\} and Eunhyang Park and Kim, \{Jae Weon\} and Lee, \{Jung Bok\} and Jinyeong Lim and Sunghoon Kim and Choi, \{Chel Hun\} and Kim, \{Hee Seung\} and Jongsuk Chung and Kim, \{Byoung Gie\} and Lee, \{Jung Yun\}",

year = "2024",

month = feb,

day = "15",

doi = "10.1002/ijc.34786",

language = "English",

volume = "154",

pages = "764--765",

journal = "International Journal of Cancer",

issn = "0020-7136",

publisher = "John Wiley and Sons Inc",

number = "4",

}

Kim, YN, Joung, JG, Park, E, Kim, JW, Lee, JB, Lim, J, Kim, S, Choi, CH, Kim, HS, Chung, J, Kim, BG & Lee, JY 2024, 'Reply to: Comments on “Randomized, two-arm, non-comparative phase 2 study of olaparib plus cediranib or durvalumab in HRR-mutated, platinum-resistant ovarian cancer: A substudy of KGOG 3045”', International Journal of Cancer, vol. 154, no. 4, pp. 764-765. https://doi.org/10.1002/ijc.34786

Reply to: Comments on “Randomized, two-arm, non-comparative phase 2 study of olaparib plus cediranib or durvalumab in HRR-mutated, platinum-resistant ovarian cancer: A substudy of KGOG 3045”. / Kim, Yoo Na; Joung, Je Gun; Park, Eunhyang et al.
In: International Journal of Cancer, Vol. 154, No. 4, 15.02.2024, p. 764-765.

Research output: Contribution to journal › Letter › peer-review

TY - JOUR

T1 - Reply to

T2 - Comments on “Randomized, two-arm, non-comparative phase 2 study of olaparib plus cediranib or durvalumab in HRR-mutated, platinum-resistant ovarian cancer: A substudy of KGOG 3045”

AU - Kim, Yoo Na

AU - Joung, Je Gun

AU - Park, Eunhyang

AU - Kim, Jae Weon

AU - Lee, Jung Bok

AU - Lim, Jinyeong

AU - Kim, Sunghoon

AU - Choi, Chel Hun

AU - Kim, Hee Seung

AU - Chung, Jongsuk

AU - Kim, Byoung Gie

AU - Lee, Jung Yun

PY - 2024/2/15

Y1 - 2024/2/15

UR - https://www.scopus.com/pages/publications/85175424233

U2 - 10.1002/ijc.34786

DO - 10.1002/ijc.34786

M3 - Letter

C2 - 37907776

AN - SCOPUS:85175424233

SN - 0020-7136

VL - 154

SP - 764

EP - 765

JO - International Journal of Cancer

JF - International Journal of Cancer

IS - 4

ER -

Reply to: Comments on “Randomized, two-arm, non-comparative phase 2 study of olaparib plus cediranib or durvalumab in HRR-mutated, platinum-resistant ovarian cancer: A substudy of KGOG 3045”

UN SDGs

Access to Document

Other files and links

Cite this